MSCV-N BNLF2a Citations (1)
Originally described in: Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins.Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Munger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M Nature. 2012 Jul 26;487(7408):491-5. PubMed Journal
Articles Citing MSCV-N BNLF2a
| Articles |
|---|
| Selected HLA-B allotypes are resistant to inhibition or deficiency of the transporter associated with antigen processing (TAP). Geng J, Zaitouna AJ, Raghavan M. PLoS Pathog. 2018 Jul 11;14(7):e1007171. doi: 10.1371/journal.ppat.1007171. eCollection 2018 Jul. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.